Humana Inc.

(New York Stock Exchange)
Back to all articles
Bullish +75

UnitedHealth or Humana: Which Managed Care Stock Had the Healthiest Returns in April?

AI-generated analysis

πŸ“ˆ UnitedHealth Group (UNH) stock surged 37% in April, finishing at $370.48 after beating Q1 2026 earnings expectations with adjusted EPS of $7.23.

πŸ”Ί Humana (HUM) stock also rallied strongly with a 36% gain, closing at $236.44 on quarterly adjusted EPS of $10.31 that slightly exceeded estimates.

πŸ’° Both insurers benefited from the Centers for Medicare & Medicaid Services (CMS) finalizing a 2% increase in Medicare Advantage payment rates for 2027, releasing over $13 billion into the program.

πŸ₯ Softer Q1 2026 hospital volumes at peer HCA Healthcare suggested lower utilization, which translated to improved medical cost ratios for managed care payers.

🌱 UnitedHealth's diversified Optum platform spanning pharmacy benefits and health services gave it a competitive edge not matched by Humana.

πŸ“‰ Despite April's success, the year-to-date recovery is broader for UnitedHealth (up 11.63%) compared to Humana (down 9.14%).

πŸ’Ό Analyst upgrades followed the earnings; Bank of America raised its price target on UnitedHealth to $435 and Guggenheim lifted Humana to $269.

πŸ‘₯ Humana reported strong individual Medicare Advantage membership growth, adding roughly 1.14 million members year-to-date with revenue up 23% year over year.

⚠️ Investors should remain cautious as regulatory risks persist, medical loss ratio pressure could reaccelerate, and valuations have stretched after the recent rally.

πŸ”„ Cash generation highlights for the recovery include UnitedHealth producing $8.91 billion in operating cash flow versus Humana's $1.25 billion, which is up 279% year over year.

🎯 The bull case relies on demographic tailwinds and specialty drug volume growth heading into the 2027 Medicare Advantage bidding process.

Bullish Signals
  • UnitedHealth stock surged 37% in April on strong Q1 2026 earnings with adjusted EPS of $7.23, significantly beating analyst expectations of $6.61.
  • Humana stock rose 36% for the month, reporting quarterly adjusted EPS of $10.31, which was slightly ahead of estimates at $10.20.
  • Both companies benefited from CMS's 2% increase in Medicare Advantage payment rates for 2027, releasing over $13 billion in additional payments into the program.
  • UnitedHealth's medical cost ratio improved 90 basis points to 84%, while Humana delivered $1.25 billion in operating cash flow, a significant 279% year-over-year increase.
  • Humana's individual Medicare Advantage membership grew about 22% year-to-date, adding roughly 1,144,000 members since the beginning of the year.
  • Management at UnitedHealth raised full-year adjusted EPS guidance to greater than $18.25, signaling confidence in future performance.
  • Humana affirmed full-year adjusted EPS guidance of at least $9 and revenue of at least $160 billion, validating its operational trajectory.
  • Analyst price targets for Humana climbed substantially, with Guggenheim raising its target to $269 and UBS lifting it to $262 from a previous low of $195.
  • UnitedHealth's diversified Optum platform provides exposure outside pure insurance that Humana cannot match, adding resilience to the business model.
  • Softer Q1 2026 hospital volumes at peers like HCA Healthcare implied lower utilization, which translates to lower medical costs for managed care payers.
Risk Factors
  • Humana stock is significantly underperforming UnitedHealth, having lost over $90 in market capitalization relative to its rival despite similar monthly rally percentages.
  • Humana remains deeply oversold with a negative year-to-date return of -9.14%, indicating lingering investor skepticism and potential downside if sentiment reverses.
  • Humana faces specific structural risks due to its heavier concentration in Medicare Advantage, leaving it more exposed to Star Ratings headwinds than UnitedHealth's diversified platform.
  • The company is subject to the v28 risk model phase-in, creating an additional regulatory uncertainty that could impact future profitability.
  • Valuations have stretched significantly after recent rallies, raising concerns that positive catalysts like cash generation may be fully priced in.
  • Despite strong Q1 results, Humana stock continues to trade down nearly 9% over the past year, suggesting broader market concerns about its recovery trajectory.
  • Analyst commentary warns that prudent investors might trim exposure into strength given the amount of good news already incorporated into current prices.
Full Analysis
In April, UnitedHealth Group (UNH) and Humana (HUM), two major players in the managed care sector, experienced significant stock rallies driven by strong quarterly earnings and favorable regulatory developments. UnitedHealth led the charge with a 37% surge to close at $370.48, following its Q1 2026 earnings report which delivered adjusted EPS of $7.23, surpassing analyst expectations of $6.61. Humana followed closely with a 36% gain to $236.44, reporting an adjusted EPS of $10.31 against estimates of $10.20 on revenue that grew 23% year-over year to $39.65 billion. Both companies benefited from the Centers for Medicare & Medicaid Services finalizing a 2% increase in Medicare Advantage payment rates for 2027, which injected over $13 billion into the program and removed regulatory pressure through the retention of the 2024 risk adjustment model. UnitedHealth further strengthened its position by improving its medical loss ratio by 90 basis points to 84% and raising its full-year adjusted EPS guidance above $18.25. The company's diversified Optum platform, encompassing pharmacy benefit management, healthcare services, and health technology, provided a buffer not available to Humana, whose stock remained down 9.14% year-to-date compared to UnitedHealth's 11.63% gain. Analysts responded positively to the results; Bank of America upgraded UnitedHealth to a Buy with a $435 price target, while Guggenheim and UBS raised their price targets for Humana to $269 and $262 respectively. However, both stocks still face bear case risks including persistent regulatory uncertainty, potential medical loss ratio pressure, and stretched valuations after the recent rally. The broader context involves a recovery from an oversold state caused by concerns over medical costs and reimbursement rates throughout 2025. Soft Q1 hospital volumes at peers like HCA Healthcare suggested lower utilization and reduced medical costs for payers, while capital rotated into these defensive names amidst volatility in AI infrastructure stocks. Cash generation remained robust, with UnitedHealth producing $8.91 billion in operating cash flow and Humana delivering $1.25 billion, a 279% year-over-year increase. Investors are now watching to see if the cost-trend thaw holds in future data regarding MLR trends and final MA rate decisions, as much of the positive news may already be priced into the stocks despite neither company having fully healed from their broader sector headwinds.